<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064792</url>
  </required_header>
  <id_info>
    <org_study_id>030225</org_study_id>
    <secondary_id>03-CH-0225</secondary_id>
    <nct_id>NCT00064792</nct_id>
  </id_info>
  <brief_title>Simvastatin Therapy in Smith-Lemli-Opitz Syndrome</brief_title>
  <official_title>Investigation of Simvastatin Therapy in Smith-Lemli-Opitz Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forbes Porter, M.D.</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of simvastatin in treating children&#xD;
      with Smith-Lemli-Opitz syndrome (SLOS). Patients with this inherited disease are deficient in&#xD;
      an enzyme that converts a substance called 7-dehydrocholesterol (7-DHC) to cholesterol.&#xD;
      Cholesterol synthesis is impaired, causing birth defects and mental retardation. This study&#xD;
      will examine whether simvastatin can increase the amount of the deficient enzyme, thereby&#xD;
      lowering 7-DHC and increasing cholesterol. It will examine the safety of simvastatin in&#xD;
      affected children and its effects on their behavioral problems.&#xD;
&#xD;
      Children between 4 and 18 years of age with mild to typical SLOS may be eligible for this&#xD;
      study. Participants will be evaluated at the NIH Clinical Center in Bethesda, MD, and at the&#xD;
      Kennedy Krieger Institute in Baltimore, MD, upon admission to the study and again at 6, 12,&#xD;
      20, and 26 months. The visits will last 3 to 4 days, and will include a medical history and&#xD;
      physical examination, photographs to document medical findings, and other procedures detailed&#xD;
      below. In addition, blood samples will be collected at 1, 3, 9, 14, 15, 17, and 23 months.&#xD;
      Parents will complete several questionnaires during the study. Procedures include the&#xD;
      following:&#xD;
&#xD;
        -  Simvastatin and cholesterol supplementation therapy. Patients take cholesterol&#xD;
           supplements (50 milligrams per kilogram per day) plus simvastatin (0.5 mg/kg/day for 6&#xD;
           weeks and then 1 mg/kg/day) for 12 months, and cholesterol supplements plus a placebo&#xD;
           for 12 months.&#xD;
&#xD;
        -  Blood draws to check liver, muscle, and kidney function, hormone levels, vitamin D&#xD;
           levels, blood counts, cholesterol and 7-DHC levels, and lipoprotein levels. Some extra&#xD;
           blood is drawn for research purposes.&#xD;
&#xD;
        -  Urine collection. Urine is collected using a toilet hat. For children who are not toilet&#xD;
           trained, urine is collected in a bag taped to the skin with an adhesive.&#xD;
&#xD;
        -  Electroretinogram (ERG) to measure the function of the retina, the light-sensitive&#xD;
           tissue at the back of the eye. ERG is done under sedation. After adapting the child's&#xD;
           eyes to the dark, an electrode is taped to the child's forehead, the surface of one eye&#xD;
           is numbed with eye drops, and a contact lens is placed on the eye. The child looks&#xD;
           inside a globe that emits a series of light flashes. The contact lens senses electrical&#xD;
           signals generated by the retina when the light flashes. After the ERG, the patient has a&#xD;
           full eye exam, including pupil dilation and photographs of the eye.&#xD;
&#xD;
        -  Lumbar puncture (spinal tap) to collect a sample of cerebral spinal fluid (CSF). This&#xD;
           procedure, done while the patient is sedated for the ERG, shows whether simvastatin&#xD;
           affects brain cholesterol and chemical levels. Under local anesthetic, a needle is&#xD;
           inserted in the space between the bones in the lower back where the CSF circulates below&#xD;
           the spinal cord. A small amount of fluid is collected through the needle.&#xD;
&#xD;
        -  CRH stimulation test to detect hormone-related problems in cholesterol synthesis. The&#xD;
           patient is given CRH, a hormone involved in cholesterol synthesis, through a plastic&#xD;
           tube placed in a vein. Blood samples are collected through the same catheter to measure&#xD;
           levels of other hormones involved in cholesterol production.&#xD;
&#xD;
        -  Electroencephalogram (EEG) to look at the electrical activity (brain waves) of the&#xD;
           child's brain.&#xD;
&#xD;
        -  Activity monitoring. An activity monitor, which looks like and is worn like a watch, is&#xD;
           used to record the child's level of activity for a 48-hour period.&#xD;
&#xD;
        -  Urine pregnancy test at every visit for female patients over age 10.&#xD;
&#xD;
        -  Skin swab for sterol (solid alcohol, such as cholesterol) analysis. An alcohol pad is&#xD;
           rubbed lightly against the child's arm or thigh to collect skin cells.&#xD;
&#xD;
        -  Stool collection. A small stool sample is collected from the child's diaper or, for&#xD;
           children who are toilet trained, from a toilet &quot;hat&quot; like that used to collect urine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smith-Lemli-Opitz syndrome (SLOS, RSH, OMIM #270400) is an autosomal recessive, multiple&#xD;
      malformation, mental retardation syndrome due to an inborn error of cholesterol biosynthesis.&#xD;
      Specifically, these patients have a deficiency of 3 beta-hydroxysterol Delta 7-reductase&#xD;
      activity due to mutation of the 3 beta-hydroxysterol delta 7-reductase gene (DHCR7). This&#xD;
      enzymatic deficiency impairs the conversion of 7-dehydrocholesterol (7-DHC) to cholesterol in&#xD;
      the last step of cholesterol biosynthesis via the Kandutch-Russel biosynthetic pathway. The&#xD;
      clinical manifestations of SLOS are extremely variable and the phenotypic spectrum is broad.&#xD;
      At the severe end of the spectrum SLOS is a lethal disorder with multiple major congenital&#xD;
      anomalies, and in mild cases SLOS combines minor physical stigmata with behavioral and&#xD;
      learning disabilities. Based on clinical studies, the incidence of SLOS is on the order of&#xD;
      1/10,000 to 1/60,000. Molecular studies have shown a carrier frequency of about 1% for the&#xD;
      most common SLOS mutant allele in North American populations. Currently therapy is based on&#xD;
      dietary cholesterol supplementation. Although clinical improvement has been noted, serum&#xD;
      cholesterol levels are rarely normalized and elevated serum 7-DHC levels persist. Because&#xD;
      elevated 7-DHC levels may have toxic effects, treatment of SLOS patients with an HMG-CoA&#xD;
      reductase inhibitor has been proposed. Two small (two-patient) open trials of simvastatin&#xD;
      therapy in SLOS have been reported. One of these trials showed improved clinical status,&#xD;
      decreased 7-DHC levels and increased cholesterol levels. The second trial showed decreased&#xD;
      7-DHC levels; however, treatment had to be discontinued in one patient with preexisting liver&#xD;
      disease. The goal of this clinical research protocol will be to test the clinical efficacy&#xD;
      and safety of simvastatin therapy in mild to classical SLOS patients using a double blinded,&#xD;
      crossover design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Cholesterol to Total Sterol Ratio</measure>
    <time_frame>1 year after therapy.</time_frame>
    <description>Total serum cholesterol (mg/dL) divided by the sum of all sterols (cholesterol plus its precursors, 7-dehydrocholesterol - 7DHC, and 8-dehydrocholesterol- 8DHC - in mg/dL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral Spinal Fluid Dehydrocholesterol to Total Sterol Ratio</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of 7-dehydrocholesterol + 8-dehydrocholesterol as a fraction of the total sterols (cholesterol + 7-dehydrocholesterol + 8-dehydrocholesterol measured in cerebral spinal fluid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Smith-Lemli-Opitz Syndrome</condition>
  <arm_group>
    <arm_group_label>OraPlus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin Susp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin Susp.</intervention_name>
    <description>During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.</description>
    <arm_group_label>Simvastatin Susp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OraPlus</intervention_name>
    <description>During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial</description>
    <arm_group_label>OraPlus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        All patients with biochemically proven SLOS will be considered for this study.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Patients will be excluded if they cannot travel to the NIH because of their medical&#xD;
        condition.&#xD;
&#xD;
        Age less than 4 and older than 18.&#xD;
&#xD;
        Weight less than 10 kg.&#xD;
&#xD;
        Developmental delay too severe to obtain adequate behavioral evaluation.&#xD;
&#xD;
        Severe behavioral problems that preclude proper physical and laboratory medicine&#xD;
        evaluation.&#xD;
&#xD;
        SLOS severity score greater than 30.&#xD;
&#xD;
        No biochemical diagnosis of SLOS.&#xD;
&#xD;
        No molecular conformation of SLOS.&#xD;
&#xD;
        Residual fibroblasts enzymatic activity less than 10% of control value (cholesterol&#xD;
        synthesis as a fraction of total sterol synthesis).&#xD;
&#xD;
        Dehydrocholesterol/cholesterol ratio greater than 1.0.&#xD;
&#xD;
        Renal insufficiency.&#xD;
&#xD;
        Contraindications for simvastatin use:&#xD;
&#xD;
        History of hypersensitivity to simvastatin or other &quot;statins.&quot;&#xD;
&#xD;
        Acute liver disease.&#xD;
&#xD;
        Persistent elevations of serum transaminase levels or persistent elevations of CPK.&#xD;
&#xD;
        Concomitant therapy with tetralol-class calcium channel blockers (such as mibefradil).&#xD;
&#xD;
        Pregnancy or lactation.&#xD;
&#xD;
        History of rhabdomyolysis or myopathy.&#xD;
&#xD;
        Concomitant therapy with other drugs associated with myopathy (such as gemfibrozil or other&#xD;
        fibrates, niacin) or metabolism by the P450 isoform 3A4 system (such as cyclosporin,&#xD;
        itraconazole, ketoconazole, macrolide antibiotics, or nefazodone (Serzone)).&#xD;
&#xD;
        Warfarin-type anticoagulant therapy.&#xD;
&#xD;
        Severe cataracts.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Forbes D Porter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2003-CH-0225.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Porter FD. RSH/Smith-Lemli-Opitz syndrome: a multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis. Mol Genet Metab. 2000 Sep-Oct;71(1-2):163-74. Review.</citation>
    <PMID>11001807</PMID>
  </reference>
  <reference>
    <citation>Kelley RI, Hennekam RC. The Smith-Lemli-Opitz syndrome. J Med Genet. 2000 May;37(5):321-35. Review.</citation>
    <PMID>10807690</PMID>
  </reference>
  <reference>
    <citation>Kelley RI. A new face for an old syndrome. Am J Med Genet. 1997 Jan 31;68(3):251-6.</citation>
    <PMID>9024554</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>July 11, 2003</study_first_submitted>
  <study_first_submitted_qc>July 11, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2003</study_first_posted>
  <results_first_submitted>July 30, 2012</results_first_submitted>
  <results_first_submitted_qc>June 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2014</results_first_posted>
  <last_update_submitted>June 4, 2014</last_update_submitted>
  <last_update_submitted_qc>June 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</investigator_affiliation>
    <investigator_full_name>Forbes Porter, M.D.</investigator_full_name>
    <investigator_title>Clinical Director, NICHD</investigator_title>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>SLOS</keyword>
  <keyword>HMG-COA Reductase Inhibitor</keyword>
  <keyword>Malformation Syndrome</keyword>
  <keyword>Mental Retardation</keyword>
  <keyword>Smith-Lemli-Opitz Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cleft Palate</mesh_term>
    <mesh_term>Hypertelorism</mesh_term>
    <mesh_term>Hypospadias</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Smith-Lemli-Opitz Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>23 subjects were consented and enrolled. 18 of 23 completed both arms of the study.</recruitment_details>
      <pre_assignment_details>Each arm of the trial (placebo then simvastatin or simvastatin then placebo) was 12 months in length. The wash out period between phases was 2 months. Each subject served as own control.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Followed by Simvastatin</title>
          <description>Subjects maintained cholesterol intake of 150mg/kg/day for 12 months. After a 2 month wash out period, they then received Simvastatin 1mg/kg/day (after starting at 0.5mg/kg/day for 6 weeks) in addition to cholesterol.</description>
        </group>
        <group group_id="P2">
          <title>Simvastatin Followed by Placebo</title>
          <description>Subjects first received Simvastatin (1mg/kg/day after starting at 0.5mg/kg/day for 6 weeks) in addition to cholesterol 150mg/kg/day for 12 months. After a 2 month wash out period, they then continued with cholesterol supplementation only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Followed by Simvastatin</title>
          <description>During the placebo phase, subjects were given a daily dose of an oral suspension not containing active drug. All subjects continued taking cholesterol suspension at 150mg/kg/day.</description>
        </group>
        <group group_id="B2">
          <title>Simvastatin Followed by Placebo</title>
          <description>Subjects began this phase by taking 0.5mg/kg/day of an oral suspension with active drug for 6 weeks followed by a daily dose of 1mg/kg/day. Subjects continued taking 150mg/kg/day of cholesterol suspension.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.576388889" spread="4.464005643"/>
                    <measurement group_id="B2" value="7.775" spread="2.286247802"/>
                    <measurement group_id="B3" value="8.175694444" spread="3.58400024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Cholesterol to Total Sterol Ratio</title>
        <description>Total serum cholesterol (mg/dL) divided by the sum of all sterols (cholesterol plus its precursors, 7-dehydrocholesterol - 7DHC, and 8-dehydrocholesterol- 8DHC - in mg/dL).</description>
        <time_frame>1 year after therapy.</time_frame>
        <population>The number of participants was determined by the total number of participants to complete both phases of the trial (n=18).</population>
        <group_list>
          <group group_id="O1">
            <title>Not Simvastatin</title>
            <description>During the placebo phase, subjects were given a daily dose of an oral suspension (OraPlus) not containing active drug. All subjects continued taking cholesterol suspension at 150mg/kg/day.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>Subjects began this phase by taking 0.5mg/kg/day of an oral suspension with active drug for 6 weeks followed by a daily dose of 1mg/kg/day. Subjects continued taking 150mg/kg/day of cholesterol suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Cholesterol to Total Sterol Ratio</title>
          <description>Total serum cholesterol (mg/dL) divided by the sum of all sterols (cholesterol plus its precursors, 7-dehydrocholesterol - 7DHC, and 8-dehydrocholesterol- 8DHC - in mg/dL).</description>
          <population>The number of participants was determined by the total number of participants to complete both phases of the trial (n=18).</population>
          <units>percent total cholesterol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.82" spread="8.52"/>
                    <measurement group_id="O2" value="93.99" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary outcome variable will be the serum cholesterol/total sterol ratio.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Spinal Fluid Dehydrocholesterol to Total Sterol Ratio</title>
        <description>Percent of 7-dehydrocholesterol + 8-dehydrocholesterol as a fraction of the total sterols (cholesterol + 7-dehydrocholesterol + 8-dehydrocholesterol measured in cerebral spinal fluid</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Not Simvastatin</title>
            <description>During the placebo phase, subjects were given a daily dose of an oral suspension (OraPlus) not containing active drug. All subjects continued taking cholesterol suspension at 150mg/kg/day.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>Subjects began this phase by taking 0.5mg/kg/day of an oral suspension with active drug for 6 weeks followed by a daily dose of 1mg/kg/day. Subjects continued taking 150mg/kg/day of cholesterol suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Spinal Fluid Dehydrocholesterol to Total Sterol Ratio</title>
          <description>Percent of 7-dehydrocholesterol + 8-dehydrocholesterol as a fraction of the total sterols (cholesterol + 7-dehydrocholesterol + 8-dehydrocholesterol measured in cerebral spinal fluid</description>
          <units>percent of total sterols</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.898" spread="4.684"/>
                    <measurement group_id="O2" value="5.154" spread="3.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <desc>muscle pain, elevated CK</desc>
      <group_list>
        <group group_id="E1">
          <title>OraPlus</title>
          <description>During the placebo phase, subjects were given a daily dose of an oral suspension not containing active drug. All subjects continued taking cholesterol suspension at 150mg/kg/day.</description>
        </group>
        <group group_id="E2">
          <title>Simvastatin Susp</title>
          <description>Subjects began this phase by taking 0.5mg/kg/day of an oral suspension with active drug for 6 weeks followed by a daily dose of 1mg/kg/day. Subjects continued taking 150mg/kg/day of cholesterol suspension.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Serious</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="01" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Pain and Elevated CK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Forbes Porter, Clinical Director, NICHD</name_or_title>
      <organization>NICHD, NIH</organization>
      <phone>301-435-4432</phone>
      <email>fdporter@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

